Jiangsu Hengrui Medicine 미래 성장
Future 기준 확인 1/6
Jiangsu Hengrui Medicine is forecast to grow earnings and revenue by 14.9% and 11.5% per annum respectively. EPS is expected to grow by 14.8% per annum. Return on equity is forecast to be 14.2% in 3 years.
주요 정보
14.9%
수익 성장률
14.8%
EPS 성장률
| Pharmaceuticals 수익 성장 | 19.3% |
| 매출 성장률 | 11.5% |
| 향후 자기자본 수익률 | 14.2% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 30 Oct 2024 |
최근 미래 성장 업데이트
Recent updates
Getting In Cheap On Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Might Be Difficult
Oct 25
Calculating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
Oct 07Revenue Beat: Jiangsu Hengrui Medicine Co., Ltd. Exceeded Revenue Forecasts By 12% And Analysts Are Updating Their Estimates
Aug 23Why We're Not Concerned About Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Share Price
Jul 03Estimating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
May 22Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Seem To Be Promising
Apr 24수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 34,469 | 8,012 | 6,688 | 7,541 | 21 |
| 12/31/2025 | 29,751 | 6,597 | 5,452 | 6,267 | 25 |
| 12/31/2024 | 27,107 | 6,000 | 4,133 | 5,198 | 23 |
| 9/30/2024 | 25,995 | 5,448 | 6,282 | 7,920 | N/A |
| 6/30/2024 | 25,252 | 5,426 | 6,338 | 7,801 | N/A |
| 3/31/2024 | 23,325 | 4,432 | 7,024 | 8,684 | N/A |
| 12/31/2023 | 22,820 | 4,302 | 6,160 | 7,644 | N/A |
| 9/30/2023 | 22,344 | 4,207 | 1,559 | 3,387 | N/A |
| 6/30/2023 | 22,216 | 4,095 | 1,797 | 3,295 | N/A |
| 3/31/2023 | 21,289 | 3,909 | -346 | 1,331 | N/A |
| 12/31/2022 | 21,275 | 3,906 | -727 | 1,265 | N/A |
| 9/30/2022 | 21,652 | 3,496 | 1,038 | 2,908 | N/A |
| 6/30/2022 | 22,836 | 3,982 | 1,144 | 3,566 | N/A |
| 3/31/2022 | 24,455 | 4,271 | 2,102 | 4,168 | N/A |
| 12/31/2021 | 25,906 | 4,530 | 2,554 | 4,219 | N/A |
| 9/30/2021 | 28,520 | 6,277 | 1,423 | 2,944 | N/A |
| 6/30/2021 | 29,723 | 6,334 | 412 | 1,554 | N/A |
| 3/31/2021 | 29,137 | 6,510 | 1,290 | 2,088 | N/A |
| 12/31/2020 | 27,735 | 6,328 | 2,878 | 3,432 | N/A |
| 9/30/2020 | 25,757 | 5,852 | 4,574 | 5,195 | N/A |
| 6/30/2020 | 24,571 | 5,577 | 5,177 | 5,741 | N/A |
| 3/31/2020 | 23,849 | 5,451 | 4,388 | 4,933 | N/A |
| 12/31/2019 | 23,289 | 5,328 | 3,255 | 3,817 | N/A |
| 9/30/2019 | 21,904 | 4,889 | 2,831 | 3,332 | N/A |
| 6/30/2019 | 19,683 | 4,568 | 2,424 | 2,899 | N/A |
| 3/31/2019 | 18,528 | 4,309 | 2,259 | 2,706 | N/A |
| 12/31/2018 | 17,418 | 4,066 | 2,245 | 2,774 | N/A |
| 9/30/2018 | 16,228 | 3,801 | 2,204 | 2,336 | N/A |
| 6/30/2018 | 15,252 | 3,553 | N/A | 2,518 | N/A |
| 3/31/2018 | 14,523 | 3,354 | N/A | 2,433 | N/A |
| 12/31/2017 | 13,836 | 3,217 | N/A | 2,547 | N/A |
| 9/30/2017 | 12,896 | 2,988 | N/A | 2,928 | N/A |
| 6/30/2017 | 12,159 | 2,848 | N/A | 2,666 | N/A |
| 3/31/2017 | 11,594 | 2,716 | N/A | 2,630 | N/A |
| 12/31/2016 | 11,094 | 2,589 | N/A | 2,593 | N/A |
| 9/30/2016 | 10,709 | 2,529 | N/A | 2,653 | N/A |
| 6/30/2016 | 10,209 | 2,425 | N/A | 2,517 | N/A |
| 3/31/2016 | 9,781 | 2,309 | N/A | 2,444 | N/A |
| 12/31/2015 | 9,316 | 2,172 | N/A | 2,277 | N/A |
| 9/30/2015 | 8,833 | 1,970 | N/A | 2,021 | N/A |
| 6/30/2015 | 8,328 | 1,817 | N/A | 1,818 | N/A |
| 3/31/2015 | 7,935 | 1,673 | N/A | 1,695 | N/A |
| 12/31/2014 | 7,452 | 1,516 | N/A | 1,574 | N/A |
| 9/30/2014 | 7,156 | 1,429 | N/A | 1,497 | N/A |
| 6/30/2014 | 6,744 | 1,356 | N/A | 1,585 | N/A |
| 3/31/2014 | 6,443 | 1,292 | N/A | 1,320 | N/A |
| 12/31/2013 | 6,203 | 1,238 | N/A | 1,365 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: 600276's forecast earnings growth (14.9% per year) is above the savings rate (2.9%).
수익 vs 시장: 600276's earnings (14.9% per year) are forecast to grow slower than the CN market (25.8% per year).
고성장 수익: 600276's earnings are forecast to grow, but not significantly.
수익 대 시장: 600276's revenue (11.5% per year) is forecast to grow slower than the CN market (14% per year).
고성장 수익: 600276's revenue (11.5% per year) is forecast to grow slower than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: 600276's Return on Equity is forecast to be low in 3 years time (14.2%).